IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
IMFINZI is the only immunotherapy approved to treat patients in this curative-intent setting following chemoradiation therapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today…